Khan Najat sold $84K of RXRX

Khan Najat (CEO and President) sold 23,588 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.58 on 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Khan Najat
Published Jun 5, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RXRX
Neutral
medium confidence
Mentioned
$RXRX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RXRXNeutralLow
01

Why it matters

The disclosed sale can influence short-term sentiment, but 10b5-1 pre-arrangement typically lowers the likelihood of it signaling new negative information.

02

Market read

A same-day insider selling print for RXRX, partially mitigated by the stated 10b5-1 plan.

03

What to watch

Consider whether other insiders also sold around the same window and whether there are concurrent clinical/regulatory updates not mentioned here.

Relevance 6/10Novelty 6/10Timing: Filed same day as the sale (2026-06-05)

Background

The article is an SEC Form 4 insider transaction disclosure for Recursion Pharmaceuticals’ CEO/President.

Company-level read

Ticker impact

$RXRXNeutralMedium confidence
Context

Recursion Pharmaceuticals CEO/President Khan Najat sold 23,588 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Likely limited immediate price impact; watch for follow-on insider activity or concurrent fundamental catalysts.

Evidence & confidence

This is an ownership-change disclosure with transaction details, but it is explicitly under a pre-arranged 10b5-1 plan, which typically dampens signal strength versus discretionary sales.

Market effects

Adds marginal sentiment noise for biotech/clinical-stage names where insider selling can be interpreted as risk appetite.

None specific beyond US small/mid-cap biotech tape.

Limited; this is company-specific insider activity.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish fundamentals.

Key entities

  • Recursion Pharmaceuticals, Inc.

    Issuer of the insider transaction; CEO/President sold shares via open-market sale under a 10b5-1 plan.

  • Khan Najat

    CEO and President; reported the sale of 23,588 shares at $3.5806/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RXRXMed

Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

$RXRXMedAI 8/10

Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

$RXRXMedAI 8/10

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

$RXRXHighAI 8/10

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.